Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

British Journal of Cancer

Volumn 113, Issue 4, 2015, Pages 585-594

  Quenel Tueux, Nathalie ^a   Debled, Marc ^a   Rudewicz, Justine ^a,b,c,d   MacGrogan, Gaetan ^a,b,c   Pulido, Marina ^a,b   Mauriac, Louis ^a   Dalenc, Florence ^e   Bachelot, Thomas ^f   Lortal, Barbara ^a   Breton Callu, Christelle ^a   Madranges, Nicolas ^a   De Lara, Christine Tunon ^a   Fournier, Marion ^a   Bonnefoi, Hervé ^a,b,c   Soueidan, Hayssam ^c   Nikolski, Macha ^c,d   Gros, Audrey ^a,b,c   Daly, Catherine ^g   Wood, Henry ^g   Rabbitts, Pamela ^g   Iggo, Richard ^a,b,c   more..

^a INSTITUT BERGONIÉ   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITÉ BORDEAUX 1   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f CLCC Lyon   (France)

^g UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

anastrozole; endocrine treatment; fulvestrant; hormone receptor positive cancer; large operable or locally advanced breast cancer; neo adjuvant

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; FULVESTRANT; GENOMIC DNA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER SIZE; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENETIC ANALYSIS; GENOMICS; HOT FLUSH; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; INVASIVE CARCINOMA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 84939202484     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.247     Document Type: Article

References (39)

1. Ali S, Coombes RC. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2(2): 101-112.
2. Carpenter R, Doughty JC, Cordiner C, Moss N, Gandhi A, Wilson C, Andrews C, Ellis G, Gui G, Skene AI. (2014). Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 144(3): 569-576.
3. Chia YH, Ellis MJ, Ma CX. (2010). Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer. 103(6): 759-764.
4. Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, Munoz C, Vega E, Calderon MJ, Sancho B, Cortes-Funes H. (2014). The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 23(3): 201-208.
5. De Censi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B. (2011). Prognostic significance of Ki-67 labeling index after short-Term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 22(3): 582-587.
6. Debled M, Auxepaules G, de Lara CT, Garbay D, Brouste V, Bussieres E, Mauriac L, MacGrogan G. (2014). Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making. Am J Surg. 208(5): 756-763.
7. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB, Miller WR. (2009). Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 113(1): 145-151.
8. Dowsett M, A'Hern R, Salter J, Zabaglo L, Smith IE. (2009). Who would have thought a single Ki67 measurement would predict long-Term outcome?. Breast Cancer Res. 11(Suppl 3): S15.
9. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. International Ki-67 in Breast Cancer Working G. (2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 103(22): 1656-1664.
10. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G. (2007). Prognostic value of Ki67 expression after short-Term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 99(2): 167-170.
11. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G. (2005). Shortterm changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 11(2 Pt 2): 951s-958s.
12. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, A'Hern R. (2006). Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 12(3 Pt 2): 1024s-1030s.
13. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M. (2001). Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 12(11): 1527-1532.
14. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 29(17): 2342-2349.
15. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von KA, Miller WR, Smith I, Eiermann W, Dowsett M. (2008). Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 100(19): 1380-1388.
16. Gusnanto A, Wood HM, Pawitan Y, Rabbitts P, Berri S. (2012). Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data. Bioinformatics. 28(1): 40-47.
17. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, Sauter G, Simon R. (2007). Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 39(5): 655-660.
18. Hostein I, Stock N, Soubeyran I, Marty M, De Mascarel I, Bui M, Geneste G, Petersen MC, Coindre JM, Macgrogan G. (2011). Nucleic acid quality preservation by an alcohol-based fixative: comparison with frozen tumors in a routine pathology setting. Diagn Mol Pathol. 20(1): 52-62.
19. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. (2004). Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 22(9): 1605-1613.
20. Jonat W, Arnold N. (2011). Is the Ki-67 labelling index ready for clinical use?. Ann Oncol. 22(3): 500-502.
21. Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ. (2012). ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol. 10(12): e1001461.
22. Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. (2012). Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 133(1): 237-246.
23. Lowe SW, Cepero E, Evan G. (2004). Intrinsic tumour suppression. Nature. 432(7015): 307-315.
24. Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R. (2011). A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 129(3): 819-827.
25. Mathew J, Asgeirsson KS, Jackson LR, Cheung KL, Robertson JF. (2009). Neoadjuvant endocrine treatment in primary breast cancer-review of literature. Breast. 18(6): 339-344.
26. Mauriac L, Debled M, Durand M, Floquet A, Boulanger V, Dagada C, Trufflandier N, MacGrogan G. (2002). Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol. 13(2): 293-298.
27. Mauriac L, Pippen JE, Quaresma AJ, Gertler SZ, Osborne CK. (2003). Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 39(9): 1228-1233.
28. Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, Barredo I, Lopez-Ruiz JA, Zabalza I, Kypta R, Vivanco M. (2014). Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med. 6(1): 66-79.
29. R Core Team. (2013). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria
30. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ. (2012). Fulvestrant 500 mg versus anastrozole. 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat. 136(2): 503-511.
31. Robertson JF, Llombart-Cussac A, Feltl D, Dewar J, Jasiowka M, Hewson N, Rukazenkov Y, Ellis MJ. (2014). Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II 'FIRST' study. SABCS S6-04
32. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 481(7381): 389-393.
33. Samarnthai N, Elledge R, Prihoda TJ, Huang J, Massarweh S, Yeh IT. (2012). Pathologic changes in breast cancer after anti-estrogen therapy. Breast J. 18(4): 362-366.
34. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. (1995). Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 180(3): 297-306.
35. Segal CV, Dowsett M. (2014). Estrogen receptor mutations in breast cancer-new focus on an old target. Clin Cancer Res. 20(7): 1724-1726.
36. Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM. (2007). Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 110(2): 244-254.
37. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G. (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 23(22): 5108-5116.
38. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. (1996). Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol. 10(11): 1388-1398.
39. Wood HM, Belvedere O, Conway C, Daly C, Chalkley R, Bickerdike M, McKinley C, Egan P, Ross L, Hayward B, Morgan J, Davidson L, MacLennan K, Ong TK, Papagiannopoulos K, Cook I, Adams DJ, Taylor GR, Rabbitts P. (2010). Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res. 38(14): e151.